Abstract.
Excessive reverse-mode sodium/calcium exchanger (RM NCX1.1) activity, resulting from Na + i accumulation due to reduced Na + /K + -ATPase activity, increased NHE1 activity and the induction of the voltage-gated sodium channel late current component (late I Na ), is a major pathway for Ca 2+ i loading in cardiac ischemia-reperfusion (IR) injury and cardiac glycoside toxicity.
Inhibition of late I Na with the anti-anginal agent ranolazine is protective in models of IR injury and cardiac glycoside toxicity. However, whether inhibition of late I Na alone is sufficient to provide maximal protection or if additional inhibition of RM NCX1.1 provides further benefit remains to be determined conclusively. Therefore, the effects of ranolazine were compared to the I Na inhibitor lidocaine in models of IR injury and ouabain toxicity, RM NCX1.1-mediated Ca
2+
overload and in patch-clamp assays of RM NCX1.1 currents. Ranolazine and lidocaine (10 µM) similarly reduced Ca 2+ i overload and improved LV work recovery in whole heart models of IR injury or exposure to ouabain (80 µM). Ranolazine (10 µM), but not lidocaine (10 µM), reduced RM NCX1.1 mediated Ca 2+ i overload in ventricular myocytes. Furthermore, ranolazine, inhibited RM NCX1.1 currents (IC 50 = 1.7 µM), without affecting forward mode currents, revealing that ranolazine has novel RM NCX1.1 inhibitory actions. However, as lidocaine provides similar protection to ranolazine in whole heart models but does not inhibit RM NCX1.1, we conclude that induction of late I Na is upstream of RM NCX1.1 activity and selective inhibition of late I Na alone is sufficient to reduce Ca 2+ i overload and contractile dysfunction in IR injury and cardiac glycoside toxicity.
Introduction
Intracellular calcium (Ca 2+ i ) overload is a key contributor to the mechanical and electrical dysfunction observed in cardiac ischemia-reperfusion (IR) injury and cardiac glycoside toxicity (Barry, 1987; Ferrari et al., 1993; Piper et al., 2003; Ruch et al., 2003; Silverman et al., 1994; Tani, 1990) . Excessive Ca 2+ influx mediated by reverse-mode (RM) operation of the cardiac Na + -Ca 2+ exchanger (NCX1.1) is thought be the major mediator of the observed Ca 2+ i overload.
Deleterious RM NCX1.1 activity occurs as a consequence of intracellular sodium (Na + i ) loading in response to 1) increased Na + influx by the Na + -H + exchanger NHE-1 (Eigel et al., 1999; Fliegel, 2009) , 2) impaired ATP availability to support Na + /K + ATPase-mediated Na + extrusion (Ju et al., 1996; Noble et al., 2006) in ischemia or direct inhibition by cardiac glycosides and more recently, 3) augmentation of a late and persistent Na + current mediated by voltage-gated Na + channels (late I Na ). Therefore, RM NCX1.1, NHE-1 and late I Na have been investigated extensively as therapeutic targets to limit Ca 2+ i overload and elicit anti-ischemic actions (Karmazyn et al., 2001; Lee et al., 2005; Moreno et al., 2012; Saint, 2008) . However, the relative importance of late I Na and RM NCX1.1 inhibition in reducing IR injury and cardiac glycoside toxicity remains to be clearly delineated.
With respect to late I Na , ranolazine (Ranexa™) is an approved drug for the treatment of angina pectoris. At therapeutic plasma concentrations (1 to 10 μM), ranolazine's anti-ischemic action is thought to arise by inhibition of late I Na (Antzelevitch et al., 2004a,b) reducing Na i + loading and thus attenuating RM NCX1.1-mediated Ca 2+ overload to decrease contractile and electrical dysfunction caused by ischemia or by selective augmentation of late I Na by Sea Anemone Toxin-II (ATX-II) Sossalla et al., 2008; Wasserstrom et al., 2009 dysfunction in a model of cardiac glycoside-induced toxicity, presumably by inhibition of late I Na (Hoyer et al., 2011) . However, it is not known whether inhibition of Na + /K + ATPase with cardiac glycosides involves augmentation of late I Na . Although NCX1.1 has been previously excluded as a target, as ranolazine has little or no effect on the physiological forward-mode (FM) activity of NCX1.1 (Antzelevitch et al., 2004a,b) , the effect of ranolazine on the pathophysiological RM NCX1.1 activity has not been examined directly. As RM NCX1.1 activity is the key mediator of Ca 2+ i overload caused either by ischemia or cardiac glycoside toxicity, the possibility remains that the beneficial effects of ranolazine may be due, in part, to direct inhibition of RM NCX1.1 activity.
Accordingly, we examined the effects of ranolazine and lidocaine, a known late I Na inhibitor (Fedida et al. 2006) , in 1) whole-heart models of IR injury and cardic glycoside toxicity 2) RM NCX1.1-mediated cellular Ca 2+ i overload independent of late I Na and 3) electrogenic FM and RM currents recorded from recombinant human cardiac NCX1.1.
Our findings indicate that ranolazine is an effective inhibitor of pathophysiological RM NCX1.1 at therapeutic concentrations, but this novel effect does not confer any additional protection over selective inhibition of late I Na alone with lidocaine and suggests that induction of late I Na is upstream of deleterious RM NCX1.1 activity in both IR injury and cardiac glycoside toxicity.
Methods

Heart perfusions and measurements of LV mechanical function in working mode
Adult male Sprague-Dawley rats (300-400 g) were anesthetized with pentobarbital (150 mg/kg i.p.) in accordance with the Canadian Council on Animal Care guidelines and the US the University of Alberta Animal Policy and Welfare Committee (protocols #027 and #152).
Hearts were excised, the aorta cannulated and a non-working (Langendorff) perfusion was initiated within 30 sec with Krebs-Henseleit solution Ju et al., 1996; Karmazyn et al., 2001 .
Heart perfusions and measurements of LV intracellular Ca
2+
Hearts were loaded with the fluorescent Ca 2+ indicator indo-1AM (5 μM) and fluorescence was measured in a ~0.3 cm 2 area of the epicardial surface of the LV free wall using This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on August 9, 2012 as DOI: 10.1124 at ASPET Journals on January 29, 2018 jpet.aspetjournals.org Downloaded from a bifurcated fiber optic cable and spectrofluorometer (Photon Technology International, London, ON) (Wang et al., 2001) . Fluorescent signals were sampled at 500 Hz and the ratio of indo-1 fluorescence emitted at 405 nm and 485 nm was calculated to give an index of beat-to-beat Ca 2+ i Wang et al., 2008) .
Experimental protocols for heart perfusions
After the indo-1 loading procedure, normal aerobic perfusion of the hearts was conducted for 15 min to obtain baseline diastolic Ca 
Cellular model of RM NCX1.1-mediated Ca 2+ -overload
Neonatal rat ventricular myocytes (NRVMs) were isolated and cultured as previously described (Kovacic et al., 2003) . After 48 to 72 hours of isolation, NRVMs were loaded with calcium green-1AM (2 μM) for 30 min at room temperature (22±1 ºC) and for 30 min at 37 ºC, and then subjected to the protocol below, as previously detailed (Eigel et al., 2001; Soliman et al., 2009) . Cells were excited with 488±10 nm wavelength light and fluorescent signals emitted at 520±10 nm were measured using a photomultiplier detection system (PTI, Photon Technology
International, London, ON). Data were analyzed using Felix32 (PTI) and Clampfit 10.1 software (Axon Instruments, Foster City, CA).
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To assess Ca 2+ i influx via RM NCX1.1 activity, NRVMs were superfused for 2 min with a solution containing (in mM): 140 NaCl, 4 KCl, 10 HEPES, 2.5 CaCl 2 , 1 MgCl 2 and 10 dextrose. Cells were then superfused with a K + -free solution (144 NaCl, 10 HEPES, 2.5 CaCl 2 , 1 MgCl 2 , and 10 dextrose) for 5 min, followed by 5 min superfusion with Na + -free solution (140 LiCl, 4 KCl , 10 HEPES, 2.5 CaCl 2 , 1 MgCl 2 , and 10 dextrose). Tetrodotoxin (TTX, 10 μM) was added to both K + -free and Na + -free solutions to inhibit cardiac Na + channels. Thapsigargin (2 μM) was added to the Na + -free solution to reduce Ca 2+ sequestration by the sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a). KB-R7943 (5 μM), ranolazine (10 μM), lidocaine (10 μM)
or NiCl 2 (5 mM) was applied during the Na + -free perfusion period to measure their effects on RM NCX1 activity. To silence NCX1 expression in NRVMs, cells were infected with an adenoviral vector encoding short hairpin RNA for NCX1 (AdshRNA-NCX1) 72 hrs prior to experiments as described previously (Soliman et al., 2009) . The AdshRNA-NCX1 construct was generously provided by Dr. Grant Pierce, University of Manitoba (Hurtado et al., 2007) .
Molecular biology, transfection and electrophysiology of NCX1.1
Mammalian expression vector plasmids containing either human NCX1.1, rat NCX1.1-F255E or human NCX1.1-K264Q constructs were transfected into cultured tsA201 cells and the whole-cell or excised inside-out patch-clamp techniques were used to measure macroscopic RM and FM NCX1.1 currents. Whole-cell patch-clamp RM NCX1.1 currents were recorded using a similar procedure to that previously described (Su et al., 1999) , with the exception that pipettes were pulled from borosilicate glass to yield resistances of 2-4 MΩ when filled with pipette solution. The pipette solution contained (in mM) NaCl 20, CsCl 130, HEPES 10, glucose 5.5, To study the inactivation kinetics, the excised inside-out patch-clamp technique was used to record RM and FM NCX1.1 currents as described previously (Hamming et al., 2008; Soliman et al., 2009) software (Axon Instruments, Foster City, CA). All experiments were performed at room temperature (22±1 °C).
Experimental compounds
Ouabain, lidocaine, thapsigargin and NiCl 2 were purchased from Sigma Aldrich (Oakville, ON). KB-R7943 and ranolazine were purchased from Tocris Biosciences (Ellisville, MO 
Data analysis and statistical methods
Data are displayed as mean ± SEM. Late NCX1.1 current amplitudes were measured and normalized to peak current. The time constant of RM NCX1.1 current inactivation (Tau, and 70% (n=5, p<0.001), respectively, of pre-ischemic baseline values (Fig 2A,B) . Recovery of coronary flow and CVC were also improved by ranolazine or lidocaine (data not shown 2C,D) . In contrast, systolic Ca 2+ i was not affected by either ranolazine or lidocaine (Fig. 2E,F) , despite the reduction in diastolic Ca In order to further investigate the underlying mechanisms for cardioprotection afforded by ranolazine or lidocaine, the Na + /K + -ATPase inhibitor ouabain was used to increase Na (Fig. 3C,D) .
Results
Attenuation of IR-induced LV dysfunction and Ca
However, systolic Ca 2+ i was not affected by either ranolazine or lidocaine (Fig. 3E,F) , despite the reduction in diastolic Ca As the effects of ranolazine on RM NCX1.1 activity have not been tested previously, yet may account for some of the protective actions of ranolazine, we sought to determine whether ranolazine directly inhibits RM NCX1 activity in an intact cellular model (Fig. 4) Fig 4A,C) . Similarly, molecular knockdown of NCX1.1 by adenoviral delivery of NCX1 shRNA (AdshRNA-NCX1) also resulted in a marked decrease in the observed Ca 2+ i signal (73.9±13.6% reduction, p<0.01, Fig 4A,C) . These data confirm that the induced Ca 2+ i overload occurring during Na + -free conditions is predominately mediated by RM NCX1.1 activity.
Using this validated cellular model of evoked RM NCX1.1 activity, the effects of ranalozine, the Na + channel inhibitor lidocaine and the NCX inhibitor KB-R7943, were compared. Ranolazine (10 μM) decreased Ca 2+ i overload by 23.6±2.6 % (p<0.001) (Fig. 4B,C) .
In direct contrast, lidocaine (10 μM) had no significant effect on reducing Ca 
Ranolazine inhibits reverse-mode current in recombinant human NCX1.1
To directly assess the effects of ranolazine on NCX1.1 activity, the whole-cell patch clamp technique was utilized to measure Ni 2+ -sensitive RM currents (Fig. 5A,F ) in tsA201 cells transiently expressing the human heart NCX1.1 splice variant. Extracellular ranolazine elicited a concentration-dependent inhibition of RM NCX1.1 current with a maximum inhibition of ~ 80% occuring at a concentration of 100 μM (IC 50 = 1.7 μM) (Fig. 5B-D) , The inhibitory effect of ranolazine (10 μM) was readily reversible after 1 min of drug washout (99.1±2.3% vs control).
In direct contrast, lidocaine (10 μM) did not significantly inhibit RM NCX1.1 currents (Fig. 5 E,F). Upon re-introduction of extracellular Na + , NCX1.1 switches to FM operation to extrude Ca 2+ from the cell, resulting in a small but measurable transient inward current (Fig. 5B) . No inhibition of this FM NCX1.1 current was observed with the application of either ranolazine or lidocaine ( Fig. 5B-E) .
As many NCX1.1 inhibitors have been demonstrated to display a selectivity for RM NCX1.1 currents displaying Na + -dependent I 1 inactivation (Iwamoto, 2004; Iwamoto et al., 2004) , the excised inside-out patch technique was used to measure RM and FM NCX1.1 currents where the inactivation kinetics are more readily observed. Whereas ranolazine (10 μM) reversibly inhibited the inactivating RM NCX1.1 currents, even a high concentration of ranolazine (100 μM) failed to inhibit the non-inactivating FM NCX1.1 currents (Fig. 6A,B ) as reported previously (Antzelevitch et al., 2004b) . To gain further insights into the mechanism of RM NCX1.1 inhibition and the relationship to the inactivation process, the effects of ranolazine on NCX1.1 K264Q and F255E mutants were assessed. RM NCX1.1-K264Q currents do not exhibit the normal characteristic I 1 inactivation and ranolazine was unable to inhibit these mutant non-inactivating RM currents (Fig. 7A) . A similar lack of effect was observed in the non- inactivating FM NCX1.1-WT currents (Fig. 7B) . Conversely, NCX1.1-F255E RM currents exhibit a faster inactivation process (τ=519±42 msec) and this was significantly accelerated by ranolazine (10 μM, τ=404±29 msec, p<0.05, Fig. 7C,D) .
Discussion
Late I Na , IR injury and cardiac glycoside toxicity.
Late I Na inhibition has been suggested to be a useful approach to reduce myocardial dysfunction associated with Na + i and Ca 2+ i overload during IR injury (Maier, 2009; Saint, 2008; Shryock et al., 2008; Stone, 2008) . Furthermore, previous studies have demonstrated that the late I Na inhibitors ranolazine and lidocaine attenuate ATP depletion during ischemia and reduce intracellular acidosis and Na + i accumulation Butwell et al., 1993) .
Indeed, our results using intact hearts confirm that ranolazine and lidocaine are equally effective in enhancing recovery of post-ischemic LV mechanical function ( Fig. 2A,B) and returning postischemic diastolic Ca 2+ i levels to near pre-ischemic values (Fig. 2C,D) , presumably via inhibition of late I Na .
Cardiac glycosides such as ouabain are useful clinically to increase inotropy of the failing heart (Kjeldsen et al., 2003; Schoner et al., 2007) and are thought to act via inhibition of Na + /K + -ATPase activity resulting in Na + i accumulation that favors RM NCX1.1-mediated elevations in Ca 2+ i and enhanced myocardial contractility (Rocchetti et al., 2003; Saini et al., 2007) . In contrast, higher concentrations of ouabain are cardiotoxic and impair LV mechanical function due to excessive Na + i accumulation that promotes NCX1.1-mediated Ca 2+ i overload. Recent studies suggest that ouabain may also induce late I Na through voltage-gated Na + channel phosphorylation by Ca 2+ /calmodulin-dependent kinase II (CaMKII) (Hoyer et al., 2011; Maltsev et al., 2008) , thus providing a mechanistic rationale for the protective effects of ranolazine reported previously in a cardiac glycoside toxicity model of ouabain-induced cardiac dysfunction (Hoyer et al., 2011) . Indeed, we found that ranolazine and lidocaine are equally effective in reducing ouabain-induced LV dysfunction and Ca 2+ i accumulation in whole hearts (Fig. 3) .
Taken together, our whole heart data support the notion that induction of late I Na is a major upstream mediator of Na + i accumulation and subsequent RM NCX1.1-mediated Ca 2+ ioverload observed in these two pathologies. This conclusion is based on several assumptions as follows: 1) that early induction of late I Na and/or elevations in Ca 2+ i are sufficient to lead to CaMKII activation and subsequent sodium channel phosphorylation and the further augmentation of late I Na that leads to Na + i loading and RM NCX1.1 activity and 2) that ranolazine and lidocaine have no effect on RM NCX1.1 activity that is a major mediator of Ca 2+ i -overload. Indeed, with respect to CaMKII, it has recently been shown that late I Na activates
CaMKII and leads to sodium channel phosphorylation and increased late I Na (Yao et al., 2011) .
However, with respect to the lack of RM NCX1.1 inhibition, the effects of these cardioprotective agents on RM NCX1.1 activity have not been tested directly until this study.
Ranolazine inhibition of RM NCX1.1 activity.
To test whether ranolazine or lidocaine inhibits RM NCX1.1 activity directly and independently of late I Na , we employed an isolated cardiomyocyte model in which TTX was included to inhibit both peak and late I Na to ensure that any drug-induced alteration of NCX1.1 mediated Ca 2+ overload would be independent of I Na inhibition. Under these conditions, ranolazine, and the NCX inhibitor KB-R7943 (Iwamoto, 2004; Iwamoto et al., 2004) inhibited evoked RM NCX1.1 activity by ~21 to 24 %, respectively (Fig. 4) . Interestingly, the I Na inhibitor lidocaine was without effect in this cellular model.
Previous studies have characterized the cardiac ion channel and exchanger pharmacology of ranolazine, including peak and late I Na , I K1 , I Kr , I to , L-type Ca 2+ channels, and NCX1.1
JPET Fast Forward. Published on August 9, 2012 as DOI: 10.1124/jpet.112.196949 at ASPET Journals on January 29, 2018 jpet.aspetjournals.org Downloaded from (Antzelevitch et al., 2004a; Antzelevitch et al., 2004b) . At therapeutic concentrations of 1 to10 μM, ranolazine inhibits late I Na more effectively than any other cardiac ion channel. It is noteworthy that ranolazine has been reported to be only a weak inhibitor of NCX1 currents (IC 50 =91 μM) (Antzelevitch et al., 2004b) . However, in that study, NCX currents were elicited by FM NCX1.1 exchange activity and effects on RM NCX1 activity were not characterized. Our comparison of ranolazine on FM and RM NCX1.1 activity provides evidence that ranolazine is an effective inhibitor of RM NCX1.1 activity at therapeutically relevant concentrations (IC 50 = 1.7 μM, Fig. 5B-D) . Furthermore, ranolazine is a selective RM inhibitor as it is unable to inhibit FM NCX1.1 activity, even at higher than therapeutic concentrations (100 μM RM-selectivity of NCX1.1 inhibitors is thought to be due to the drug binding to exchangers undergoing the I 1 -inactivation process, a characteristic of RM, but not FM NCX1.1 currents (Bouchard et al., 2004; Elias et al., 2001; Hamming et al., 2008) . To assess whether the RM selectivity of ranolazine is similarly dependent on the I 1 -inactivation process, we measured the effects of ranolazine on RM currents arising from NCX1.1 exchangers with altered I 1 -inactivation properties (Matsuoka et al., 1997) . While ranolazine did not inhibit the noninactivating RM current of the K264Q mutant NCX1.1, it further accelerated the rate of current inactivation in NCX1.1 containing the F255E mutant that displays an increased rate of inactivation (Fig. 7) . Taken together, these findings support our conclusion that ranolazine is a RM-selective inhibitor of NCX1.1 activity and that it possesses a mechanism of action similar to other known NCX1.1 inhibitors.
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In summary, our results indicate that ranolazine and lidocaine are equally effective in reducing contractile dysfunction and Ca 2+ loading in whole-heart models of IR injury and cardiac glycoside toxicity. In addition, ranolazine, but not lidocaine, has a direct inhibitory effect on cardiac RM NCX1.1 activity. Taken together, these results suggest that late I Na is involved in both IR injury and cardiac glycoside toxicity and that the observed RM NCX1.1 inhibitory effects of ranolazine do not confer any additional protection in these models. Therefore, induction of late I Na is likely upstream of RM NCX1.1-mediated Ca 2+ overload and that the observed inhibition of RM NCX1.1 activity with ranolazine does not confer any additional protection over late I Na inhibition alone in models of IR injury and cardiac glycoside toxicity. denoted by *,**,*** for p<0.05, p<0.01 and p<0.001 respectively. Analysis of the timedependent changes were performed by repeated measures ANOVA. and shRNA-NCX1 knockdown of NCX1.1 expression (n=6). **p<0.01, ***p<0.001 when compared with untreated group; paired Student's t-test. This article has not been copyedited and formatted. The final version may differ from this version.
